Market Overview

UPDATE: Piper Jaffray Cuts PT to $35 on Sarepta Therapeutics on Share Dilution; Regulatory Outlook Positive

Share:
Related
Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval
Mid-Day Market Update: Starwood Hotels Jumps Following CEO Resignation; CoStar Group Shares Slide
Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on Q4 2014 Results -- Earnings Call Transcript (Seeking Alpha)

Piper Jaffray reiterated its Overweight rating on Sarepta Therapeutics (NASDAQ: SRPT) but reduced its price target from $38 to $35.

Piper Jaffray said, "Sarepta raised net proceeds of ~$118 million in December, bringing pro forma cash to >$175 million to advance eteplirsen and other Duchenne Muscular Dystrophy (DMD) exon skipping drugs. The primary driver remains eteplirsen, for which Sarepta hopes to hold an end-of-Phase II meeting with the FDA, likely this quarter. Based on that meeting, Sarepta may seek accelerated approval of eteplirsen under PDUFA V. We continue to believe the drug meets the requirements for a Breakthrough Therapy. We reiterate our Overweight rating, however are trimming our price target to $35 from $38 to account for dilution from the recent deal."

Sarepta Therapeutics closed at $25.80 on Monday.

Latest Ratings for SRPT

DateFirmActionFromTo
Feb 2015Cowen & CompanyDowngradesOutperformMarket Perform
Feb 2015Bank of AmericaUpgradesBuy
Jan 2015WedbushInitiates Coverage onNeutral

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (SRPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content